{"ticker": {"uuid": "ba04ea8d-2432-48e8-bb8d-11449de0c763", "symbol": "DFTX", "name": "Definium Therapeutics, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology", "summary": "Definium Therapeutics has launched \"Wired for Worry,\" an educational initiative for healthcare providers focusing on Generalized Anxiety Disorder (GAD). This program aims to deepen understanding of GAD's symptoms, lifelong impact, and neurobiology, as well as the importance of ea", "url": "https://www.morningstar.com/news/business-wire/20260709964486/definium-therapeutics-launches-wired-for-worry-a-health-care-provider-initiative-to-advance-the-understanding-of-generalized-anxiety-disorder-gad-patient-impact-and-neurobiology", "source_name": "Morningstar", "published_at": "2026-07-16T10:41:28", "published_display": "16 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Inc. (DFTX) News, Articles, Events & Latest Updates", "summary": "This page provides a collection of recent news, articles, and updates concerning Definium Therapeutics Inc. (DFTX), a late-stage clinical biopharmaceutical company. Key topics include analyst price targets, a new healthcare claims study on Generalized Anxiety Disorder, positive c", "url": "https://stocktwits.com/symbol/DFTX/news", "source_name": "Stocktwits", "published_at": "2026-07-16T04:39:56", "published_display": "16 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Could Be 30% Overvalued After New GAD Study", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T22:45:43+00:00", "published_display": "15 Jul 2026 22:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOc2JiOGhCd0l2RjM3SHhUX3Z3cWJSTkhSWGtrQXFFcEtTMU8zNEZtSnVaaHBXbWx2c1NaYk5CMHJRWFc5cHdrRnJLRUVvSEFKVXQyb2kybDcxTk9kQ29VYUE3bTRLOGR3T2ZtODBKRndFQmlBWUFOWDR0VVl1elB0dzlkTWtObFUwakV6Y29GdTY5WGh2RW02MmFnZ3ZWdw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T09:24:34+00:00", "published_display": "15 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will New GAD Treatment Persistence Data Change Definium Therapeutics' (DFTX) Unmet\u2011Need Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-14T18:48:21+00:00", "published_display": "14 Jul 2026 18:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNWm9qVWUyX1pjcjlvLUxKM1g4UHJEMEd2MmduU2lyd1BReG44M1FYcEgyeHBDOHVJNmNsblFpa0UtMGxOanVFM1B0aEQ5cHFZNkdZblUzQW5Ba0Jpb2NsaDVmR1Bad2FKWEVXUXRiN0ZKYnE2OC1zZXc3Z0o0Szc0U0lkSlNJT043blRZbEI3T21hbVU3SFpxTDMtaEt0T0ZCLXc?oc=5", "source_name": "Market source", "published_at": "2026-07-14T13:55:04+00:00", "published_display": "14 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc. Announces Results from New Healthcare Claims Study of Treatment Patterns of Newly Diagnosed and Established Gad Patients, Including Pharmacotherapy Use, Discontinuation, Switching and Treatment Progression", "summary": "Definium Therapeutics, Inc. announced results from a new healthcare claims study revealing significant unmet needs in Generalized Anxiety Disorder (GAD) treatment. The study, published in CNS Spectrums, highlights frequent discontinuation, switching, and prolonged gaps in care am", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-announces-results-from-new-healthcare-claims-study-of-treatment-patterns-ce7f5edcd08df627", "source_name": "marketscreener.com", "published_at": "2026-07-14T11:40:30", "published_display": "14 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More Than Half of Newly Diagnosed GAD Patients Stopped Therapy", "summary": "A new healthcare claims study published in CNS Spectrums by Definium Therapeutics (DFTX) reveals that 55% of newly diagnosed Generalized Anxiety Disorder (GAD) patients discontinued their initial pharmacotherapy. The study highlights significant unmet needs in GAD treatment, with", "url": "https://www.stocktitan.net/news/DFTX/new-healthcare-claims-study-published-in-cns-spectrums-finds-high-sg82nf1oclaf.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:40:30", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Definium Therapeutics (DFTX) Following Russell Index Removal And The Fair Value Debate", "summary": "Definium Therapeutics (DFTX) is gaining attention after its removal from Russell indexes, with its stock showing significant recent momentum. While one analyst narrative suggests the stock is overvalued at $44.33 with a fair value of $35.23, based on its clinical pipeline and fut", "url": "https://www.sahmcapital.com/news/content/definium-therapeutics-dftx-following-russell-index-removal-and-the-fair-value-debate-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-09T02:40:56", "published_display": "09 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $60", "summary": "Stifel has reiterated its Buy rating on Definium Therapeutics (DFTX.US) and increased the target price to $60. This continued positive outlook from Stifel suggests confidence in the company's future performance and valuation. The raised target price indicates an expectation of si", "url": "https://www.moomoo.com/news/post/72649606/stifel-maintains-definium-therapeutics-dftxus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-09T02:09:01", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Inc (DFTX) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary", "summary": "Definium Therapeutics Inc. presented at the Canaccord Genuity 44th Annual Growth Conference, detailing clinical development for MM120 and MM402. MM120 is advancing to Phase III trials for GAD and MDD, demonstrating durable effects from a single dose, while MM402 is in Phase I for", "url": "https://quartr.com/events/definium-therapeutics-inc-dftx-canaccord-genuity-44th-annual-growth-conference-private-comp_ojsyZ2LG", "source_name": "Quartr", "published_at": "2026-07-09T02:09:01", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel raises Definium Therapeutics price target on MDD data", "summary": "Stifel increased its price target for Definium Therapeutics (NASDAQ:DFTX) to $60 from $30, maintaining a Buy rating after strong MDD data for DT120. The firm believes the data significantly de-risks the program and could lead to peak revenues exceeding $4 billion. Definium Therap", "url": "https://www.investing.com/news/analyst-ratings/stifel-raises-definium-therapeutics-price-target-on-mdd-data-93CH-4780314", "source_name": "Investing.com", "published_at": "2026-07-07T22:13:41", "published_display": "07 Jul 2026 22:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Announces New Employee Inducement Grants", "summary": "Definium Therapeutics, Inc. announced the issuance of inducement grants to eight new non-executive employees. These grants consist of options to purchase an aggregate of 169,740 common shares, vesting over four years. The grants were approved by the company's Compensation Committ", "url": "https://www.businesswire.com/news/home/20260706280056/en/Definium-Therapeutics-Announces-New-Employee-Inducement-Grants", "source_name": "Business Wire", "published_at": "2026-07-06T20:10:01", "published_display": "06 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Phase 3 DT120 ODT Results in Depression Could Be A Game Changer For Definium Therapeutics (DFTX)", "summary": "Definium Therapeutics announced positive Phase 3 results for its DT120 ODT in major depressive disorder, with the Emerge study meeting its primary and secondary efficacy endpoints. This success strengthens the investment narrative for DFTX, despite previous concerns about funding", "url": "https://www.sahmcapital.com/news/content/positive-phase-3-dt120-odt-results-in-depression-could-be-a-game-changer-for-definium-therapeutics-dftx-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-06T01:13:41", "published_display": "06 Jul 2026 01:13", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Definium Therapeutics, Inc. \u2013 NASDAQ:DFTX", "summary": "This article provides financial data for Definium Therapeutics, Inc. (NASDAQ: DFTX), specifically focusing on its Enterprise Value to EBITDA forward metric. The content highlights the company's financial overview on TradingView, indicating that the market is closed with no trades", "url": "https://www.tradingview.com/symbols/NASDAQ-DFTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:42:52", "published_display": "04 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DFTX - Definium Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Definium Therapeutics Inc (DFTX), covering its stock performance, key financial metrics, volatility, and various Greek parameters relevant for options trading. It includes data such as market capitalization, income, sales, EP", "url": "https://finviz.com/stock?t=DFTX&ty=ocv&p=m&ov=chain_strike&s=3", "source_name": "Finviz", "published_at": "2026-07-02T15:39:15", "published_display": "02 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSD therapy biotech Definium fends off trade-secret lawsuit", "summary": "A federal judge in Delaware dismissed a trade-secret lawsuit against psychedelic therapy developer Definium Therapeutics, filed by clinical-trial provider Signant Health. The judge ruled that Signant's complaint failed to adequately identify protectable trade secrets. Definium, f", "url": "https://www.reuters.com/legal/litigation/lsd-therapy-biotech-definium-fends-off-trade-secret-lawsuit-2026-07-01/", "source_name": "Reuters", "published_at": "2026-07-01T17:09:00", "published_display": "01 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Completes $805 Million Upsized Public Offering", "summary": "Definium Therapeutics, Inc., formerly Mind Medicine, a late-stage clinical biopharmaceutical company, has successfully completed an upsized $805 million public offering. Hogan Lovells advised Definium Therapeutics on this transaction. Access to the full details of the offering re", "url": "https://globallegalchronicle.com/post-236159/", "source_name": "Global Legal Chronicle", "published_at": "2026-07-01T00:39:56", "published_display": "01 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)", "summary": "Two healthcare stocks, Crinetics Pharmaceuticals (CRNX) and Definium Therapeutics (DFTX), have received bullish ratings from analysts. Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating for Crinetics Pharmaceuticals with an $83.00 price target, while Paul Matteis a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DFTX/pressreleases/3047465/analysts-are-bullish-on-top-healthcare-stocks-crinetics-pharmaceuticals-crnx-definium-therapeutics-dftx/", "source_name": "The Globe and Mail", "published_at": "2026-06-30T22:41:00", "published_display": "30 Jun 2026 22:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?", "summary": "Definium Therapeutics, Inc. (NASDAQ:DFTX) recently received a positive update from Robert W. Baird analyst Christopher Chen, who increased the company's price target to $57 from $37, maintaining an Outperform rating following positive Emerge trial results. The biopharmaceutical c", "url": "https://www.insidermonkey.com/blog/is-definium-therapeutics-inc-dftx-stock-poised-for-further-gains-after-positive-emerge-trial-update-1791987/", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:39:56", "published_display": "30 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord cuts Definium Therapeutics stock price target on share count", "summary": "Canaccord has lowered its price target for Definium Therapeutics (NASDAQ: DFTX) to $58 from $60, while maintaining a Buy rating. This adjustment follows a recent share offering by the company, increasing the share count, but the firm's unadjusted sales projections for its drug ca", "url": "https://www.investing.com/news/analyst-ratings/canaccord-cuts-definium-therapeutics-stock-price-target-on-share-count-93CH-4767600", "source_name": "Investing.com", "published_at": "2026-06-30T11:39:11", "published_display": "30 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000 Value Benchmark", "summary": "Definium Therapeutics, Inc. (NasdaqGS:DFTX) has been removed from the Russell 3000 Value Benchmark. The company, known for developing therapeutics for psychiatric and neurological disorders, is currently trading at $46.55, up 3.56% after hours. Recent news includes its entry into", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-nasdaqgs-dftx-dropped-from-russell-3000-value-benchmark-ce7f5fdeda8cf422", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:55:00", "published_display": "29 Jun 2026 12:55", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Definium Therapeutics, Inc. (NasdaqGS:DFTX) has been removed from the Russell Small Cap Comp Value Benchmark. The company, formerly known as Mind Medicine (MindMed) Inc., is focused on developing therapeutics for psychiatric and neurological disorders, with its lead candidate, DT", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-nasdaqgs-dftx-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8af124", "source_name": "marketscreener.com", "published_at": "2026-06-29T10:10:20", "published_display": "29 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000E Growth Benchmark", "summary": "Definium Therapeutics, Inc. (NasdaqGS:DFTX) has been removed from the Russell 3000E Growth Benchmark. Despite this change, the company continues to advance its pipeline of therapeutics for psychiatric and neurological disorders, including DT120 ODT, which has received FDA Breakth", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-nasdaqgs-dftx-dropped-from-russell-3000e-growth-benchmark-ce7f5fdedf89f625", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:41:42", "published_display": "29 Jun 2026 08:41", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc.(NasdaqGS: DFTX) dropped from Russell Microcap Index", "summary": "Definium Therapeutics, Inc. (NasdaqGS: DFTX) has been removed from the Russell Microcap Index. The company is focused on developing therapeutics for psychiatric and neurological disorders, with a lead candidate, DT120 ODT, targeting generalized anxiety disorder (GAD) and major de", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-nasdaqgs-dftx-dropped-from-russell-microcap-index-ce7f5fdeda80ff21", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:41:42", "published_display": "29 Jun 2026 05:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Definium Therapeutics, Inc. \u2013 NASDAQ:DFTX", "summary": "This article displays a financial metric, the \"Price to sales forward,\" for Definium Therapeutics, Inc. (NASDAQ: DFTX). It presents this data within the TradingView platform's market analysis section, indicating that it is a snapshot of financial performance for the company. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-DFTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:39:40", "published_display": "28 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Definium Therapeutics, Inc. \u2013 NASDAQ:DFTX", "summary": "This article provides financial information for Definium Therapeutics, Inc. (NASDAQ: DFTX), specifically focusing on its forward price-to-earnings ratio. It is presented in a data-centric format from TradingView, indicating market status, and links to various financial data sourc", "url": "https://www.tradingview.com/symbols/NASDAQ-DFTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:11:05", "published_display": "27 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Definium Therapeutics, Inc. \u2013 HAM:MMQ0", "summary": "This article provides the \"Price to book forward\" for Definium Therapeutics, Inc. (HAM:MMQ0), a pharmaceutical company listed on the Hamburg Stock Exchange. The current market status is closed with no trades. The information is presented within the TradingView platform, which off", "url": "https://www.tradingview.com/symbols/HAM-MMQ0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:11:05", "published_display": "27 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings ratio of Definium Therapeutics, Inc. \u2013 HAM:MMQ0", "summary": "The article focuses on the price-to-earnings ratio of Definium Therapeutics, Inc. (HAM:MMQ0), a company listed on the Hamburg Stock Exchange. It provides financial overview, but no actual ratio is displayed, indicating that the market is closed with no trades.", "url": "https://www.tradingview.com/symbols/HAM-MMQ0/financials-statistics-and-ratios/price-earnings/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:13", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Definium Therapeutics, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Definium Therapeutics, Inc. It provides a detailed table with each ETF's market value, weight of Definium stock, issuer, management style, focus, expense ratio, assets under management (AUM), current pric", "url": "https://www.tradingview.com/symbols/HAM-MMQ0/etfs/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:13", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium (DFTX) CEO sells 29,208 shares to cover RSU tax obligations", "summary": "Definium Therapeutics, Inc. CEO Robert Barrow sold 29,208 common shares at $45.03 each on June 25, 2026. This transaction was conducted to satisfy withholding tax obligations related to vested restricted stock units under a pre-arranged Rule 10b5-1 sell-to-cover plan. Following t", "url": "https://www.stocktitan.net/sec-filings/DFTX/form-4-definium-therapeutics-inc-insider-trading-activity-f11cef1c86bf.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:40:13", "published_display": "26 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Definium Therapeutics, Inc. Insider Trading Activity", "summary": "Definium Therapeutics CFO Brandi Roberts disposed of 3,013 common shares at $45.03 each on June 25, 2026. This transaction was a \"sell-to-cover\" event to satisfy tax obligations from vested restricted stock units, executed under a pre-arranged Rule 10b5-1 trading plan. Following ", "url": "https://www.stocktitan.net/sec-filings/DFTX/form-4-definium-therapeutics-inc-insider-trading-activity-ada560f26a68.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:30:37", "published_display": "26 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Lands Phase 3 Win And Raises $700 Million For DT120", "summary": "Definium Therapeutics (NasdaqGS:DFTX) announced positive topline Phase 3 results for DT120, its major depressive disorder treatment, and simultaneously completed a US$700 million equity offering. This funding is intended to support the regulatory and commercialization efforts for", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/definium-therapeutics-dftx-lands-phase-3-win-and-raises-700", "source_name": "Simply Wall Street", "published_at": "2026-06-26T13:40:26", "published_display": "26 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium closes $805M upsized stock offering | DFTX Stock News", "summary": "Definium Therapeutics, Inc. announced the closing of its upsized underwritten public offering, raising $805 million. The offering included the full exercise of the underwriters\u2019 option to purchase additional shares, with all 23,676,471 common shares sold at $34.00 each. Definium ", "url": "https://www.stocktitan.net/news/DFTX/definium-therapeutics-inc-announces-closing-of-805-million-upsized-umbrglb2boxi.html", "source_name": "Stock Titan", "published_at": "2026-06-26T09:41:42", "published_display": "26 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Closes Public Offering of Common Shares", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/definium-therapeutics-closes-public-offering-210201361.html", "source_name": "MT Newswires", "published_at": "2026-06-25T21:02:01+00:00", "published_display": "25 Jun 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Definium Therapeutics (DFTX) Is Up 49.8% After DT120 Phase 3 Win And $700 Million Raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPcFRqUTZRRlBUaktHX2E3U096V25PWWJRUzh3YXJ1X0ZUVHNUNk9xendjY25CWVV5TXJ5N09jVmF1TV9EcUNhVUxHSUdHbmtkeWxCM1B2czdfbzBNVEw0bTRFQ2dYOTVaNnp2TlpLQWE1TFRwOGFCVzJUZkJ6RzdaTTBMb2ZFZjg3U1A4VnNwUHFIM1Nyb1lmaFZB?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPV0xlbTIxelBIUV9wWm9PYzUxZ3IxOTQwaFJQTDQwQWZYVVd6ODZhRnhmM2dEWDV1RzdTTkwxOUxvZWQ0TWhEbzYxWXBRRmY0ZHdKQkFSajExcFY4WldOWE9kd254amhwZUszdk5xR3RwNDM3aFZua3ZaWGtya3pnSHJLUFUyc3NvQjlZZXl3ODNBRy1Sb1BfVmRhVlo5U2pjYnB2Zy00VlU1aGhRRUlVUFRXLVdaNVZqcUc1eUQtUzR2WTQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Posts Phase 3 Win And Plans Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPZVJTX1JXeHYyb0FHZFJPdjRIVnJ2d0djdHVXOU5KZm1hc2lrRnl5aU5RUXVCLUpqZU05NzJnV2RnMnlCdU8yNjFIQWhReW5JUl9sUEZVeHFmN3h5allyMXNrbEFhaXNGNXJ5MzI0SWFhVU5DR3FXaHpaMm44SF9hTHlvbzh6U1Q5cnI4aS1CbE9qY3ByZHBacS0wVkJaei1B?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics seeks $500M in a public share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVEdZSVJYUlNEUk80alhqTVFlbXgzdEs5YVY4QWQ5c2xJWUR0SkIzUDJmYWxlNVhhZjRJTmhLbTBrNHZFTWZyRlVITzlsR1JWazBtVU5ZdTItNkdJRFJaamtyQ2NRdWJwUlZFQnJMOHdsWW5mZFZqdnpLZXR0RXdLR3FQeWVsQ015Q0FkRmNmMGoycUtYT3hFVW15LVdlTVVFWWk3UGpIWnk2Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T20:03:47+00:00", "published_display": "22 Jun 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink raises Definium Therapeutics stock price target on MDD data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPZWJhNkVTV2U0TWVaX2RQNUhFS3J4eTBlRkk0MTZQN0hPMEk1bG1DQnlqZ0c2Q3BWVGR5OU5ZVWVhSEIwYTVocW05UldlQVdqaHFSZldQZ2lEQ29GVVY2aWdRb21OakwxNkd0OW9rSjJkU0ZfbEdtb1hyOHY3YWFqMnhYYXpJWDBTYkpUU3RFQTlRZDZvV05BOWVEdjZyWlJlQjZSTldULUVkNzdZajNtOWoxQ0MtWkhXZTk0bHQ4blRDQ2NfWkE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) reports positive Phase 3 Emerge results for DT120 ODT in major depressive disorder", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOWFVtRlB4c19jUVNUaHJaR21QUlVzT2FNaXNXbVk0UlZsRUcwaGh3YWphRVdFTUVCSENnVW54VGFxZlFrNjRyNk13QWw3RHZEMzRmSHNvODlRVTVvdFItcmpEZ0NsdXVqeEtCczFSc1l6MUZNMTNWNnR3bG5NSzRROHpmN1BiQXBOSldKb3BQU1p5Ui1HbURDbmdQYXo5Vzd4VlJoWmtZajlrSXN1ZjQ5ZjNFWXI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) CEO receives 375,000 performance share units", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTkotMmxQME14dktRYmtXOUpvZ2JyeU83WjEyVmFEbXI1OEZsR05tc1kyYUpBTDdmdlIzVlI5Nl90WGxiUzVSWDdfWTFZU1lKak4xMWdSOHBGUmJjdFpMMzRwVjFRMzRyZjA0QzJwOFpidWc4cGI3MHItdUdCRXc5cFhUb1VOZDlQdWwzQUhHS1JqTVpYM0lMWmk4blQ1bUdoZjgxcTFjVU03elc1aDB3ejNCX2ZJZHFjbFI0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Hits New High on Impressive Drug Candidate Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcEdETjlPUTZ5N0swLUVza1RrZDNkZEQ1WFN3TjE5eGhvdkc5UFE0Tk1VTDl3a1dfOFA5QVdiMWZ4dkRGUzFnT25qWWtXZHRKWUJXeVhwbWw1M0ZQbGZ2YjcyYmlwc1NNcjUzTUpqaFVDd1RhN2dmaUYyeXA5UnhZZEpyUV9kX2V3aUZPdDBkS2lETnIxRGkwSnAzTVFJdw?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium sets webcast on Phase 3 depression study results for June 22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQX3doMktpbktIaUxiVm1helUxUXdHbUQwTFZTOFpkUkpUYWVyV3RYNlJDWDFoeThCUXVqbklBanEtTVZyTWFrYjMweHhDT0wtaDN3QmJBZnJZNkJUVXJVNUdJNG9INjB6VkpkbHlCOVFCTnhEZFRwWnFHdUxvZWNpdjdaQy1wZ2wyQ2k2N1pxOUFjQjhZUDlXQ0dEeGFTckp2UEljejdyRG5NcFZNQzFSRGtlUVMxdTAtUlFscHhoNHE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) awards RSUs and stock options to director Krebs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPb0piR1hoMW11akRuVWxLT2xvZGZCMVYwbEY0Mm1IcWlPeW1PN042SXQ3UEpWSG9LYktyZkxJbnp5MjFFWWdsRzFIV202SDcwVUpnb2h0ZTh1UUxBYk8xMmtQYjU4cXRuV2dld0tycDB2UXMyRWhLbzNfZ1NzWHY4c2RoOEowcnFXaXdkalhZRk5ack5sSVJwSmJUMmtnenFBSjN2MnlSSGMtcVI5OWFodVUtWE51c1RJbWdr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) director receives RSU and stock option grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUk9Ma1lIWjQzWXYtTGF4SlBaU1dhYUl0bWsyTGgtRGdCQ1FUOV9PcUVIT0hzZjR0M284UTV1WFRNMFZYeU5tbWJRNkdhQVBPcXYwRVJMdHBjank3WHpIN0xVUUZLRDlfcVh6VXdSb2l5T01VR2R3NEpwNDRrbmpWd2JtcE9uUVBaTTBlWmJZOWM2X0NoR19FY3dQNHRZSk9sMkItLVNJVXZmMVlNV0VkUy1NVmFUYnhLbEhF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Definium Therapeutics (DFTX) Valuation As Shares Show Strong Recent Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNS0dKMzh1YnM4dUpEeFN1WGs0Z0xVbDEzRDh2aXJJbnIzaHlSTDJuS0FSQUlxM1Fub2lhRzg5QVlCX0lTXzU1clNRU1FvSmtVUDRINklXMjljamZSQkNJVDZrRGI1SVFmcXV5ZTV3TFVERVNkak0yZlpNci1qWWVCUWpHZUs0VGVJQUxNeUp5TkFBTXEwT2ROSHlsZmJXZnJFRTlkajRaUS0wTVprX3Nn?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Definium Therapeutics (DFTX) Begins Phase 3 Study for Major Depr", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPTzBrVG9reTlCaE51UE1KbjlNOGxkLWxtX01MYXVfSlJ2WHlvX05rVVR5MUdxckZVSHFRX2tGWEdhclgtc0FfeDRObGdpNnBIMXE0aExQSF9VdkhMNlZOYmg5ZHVzZkF5WTBjMXhjd09LRmxnM1E0RW5TenV1clJ3WnpjSk1WMnpsR3Rocnl4bkZzYlY0T0d0d0RMSEpxS3l4N0xMeTNCMjlzQWlCV0pDU2RhV3JiNTVISTAzTFZfcWhrOFZQLWVF?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPcEhCcHZzeVY4bjNmYWkxTmhtanhPUFhEa0VoVGRFbnZTaU4zVWhIdkdRTF84QVU0TXM4T291cld6cF9uZzhQaE0xNWdGa3YxSksyMk82V0tFWnVLR05TMTUxXzRTVjdHLWRuejYyRHFSTGNxQkw1SVJjZHcwWHpRd0dwMXIyTGJ5aWMtVkowUW1LUExwQjUxRXZoV2pRZi1WNENFejNfVVJOTEllSUFB?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Definium\u2019s Q1 2026 EPS miss overshadows strategic advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQNGtjYXJFZ3VQaklnZ2J1NzR0MU56UlRPczJJMXJBLU9QSHF1OXFyWEtiMnJrYi1tNUhVQ05DOFA0d2VMR0szUTV1SUJOZnFnS1hqNWZxWnplX1Rnb0plUklwS1MzbF9kYW44ZnVjTXBWaXRaWXROWmcxdHJ6VEVNc3BfVjNERzV0VktIOW9CUmpwVnNteUYzYnQtNXFCaUVWcmRJeDlBMzFvWHBoTFloZkttck1QbVlHYmhTblh3SThwcTF1aUpiYTM4ZEhORkYxSEdtbw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Definium Therapeutics stock hits 52-week high at 25.63 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQZDJqNlgxbVRDci12TWYwQVVsTm9EVUZ4Q2VmbG9QTjFraWNBUlIwTDdCWW4wMFFCak9EdWt1ODhDbElPRjJVX25ZOVBoNDRwSDFUS1dMNWRJSTNPWTNaT1RWS3puUjN1Qkl3SGtoX3h0M0ZhYVVONlF6cFhWdlJySHlpVWY1UDBhYXI3SU5qaVk5bG9CaGk4TFJOX1N3cmw4N1J5dlhEZkRVNkZkSnk3NE9obw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics stock hits 52-week high at 21.99 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOT0FRa3VNRnMyRnNlZDFMcFhWT3lFTDBTMUs1SGRYMENoREdUcGs3bUJpT2ZNb2FqU1FjeHF3U2xSdURvVDdmRUZvSVVURXh3MkEweUdqZ29yZEk3YzAyRmo2d0VtVmhJWGVwVXE2dmJVeUdUSXFLTXg4Rk5pbC04ZTFCWmVZc19vQ2RtaWhnc1BWYnF4MTJjV2ZpUWxjQzBHTVJHaDZBcTJtUUJoQm9sd283RQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology", "summary": "Definium Therapeutics has launched \"Wired for Worry,\" an educational initiative for healthcare providers focusing on Generalized Anxiety Disorder (GAD). This program aims to deepen understanding of GAD's symptoms, lifelong impact, and neurobiology, as well as the importance of ea", "url": "https://www.morningstar.com/news/business-wire/20260709964486/definium-therapeutics-launches-wired-for-worry-a-health-care-provider-initiative-to-advance-the-understanding-of-generalized-anxiety-disorder-gad-patient-impact-and-neurobiology", "source_name": "Morningstar", "published_at": "2026-07-16T10:41:28", "published_display": "16 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Inc. (DFTX) News, Articles, Events & Latest Updates", "summary": "This page provides a collection of recent news, articles, and updates concerning Definium Therapeutics Inc. (DFTX), a late-stage clinical biopharmaceutical company. Key topics include analyst price targets, a new healthcare claims study on Generalized Anxiety Disorder, positive c", "url": "https://stocktwits.com/symbol/DFTX/news", "source_name": "Stocktwits", "published_at": "2026-07-16T04:39:56", "published_display": "16 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Could Be 30% Overvalued After New GAD Study", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T22:45:43+00:00", "published_display": "15 Jul 2026 22:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOc2JiOGhCd0l2RjM3SHhUX3Z3cWJSTkhSWGtrQXFFcEtTMU8zNEZtSnVaaHBXbWx2c1NaYk5CMHJRWFc5cHdrRnJLRUVvSEFKVXQyb2kybDcxTk9kQ29VYUE3bTRLOGR3T2ZtODBKRndFQmlBWUFOWDR0VVl1elB0dzlkTWtObFUwakV6Y29GdTY5WGh2RW02MmFnZ3ZWdw?oc=5", "source_name": "Market source", "published_at": "2026-07-15T09:24:34+00:00", "published_display": "15 Jul 2026 09:24", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will New GAD Treatment Persistence Data Change Definium Therapeutics' (DFTX) Unmet\u2011Need Narrative?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-14T18:48:21+00:00", "published_display": "14 Jul 2026 18:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNWm9qVWUyX1pjcjlvLUxKM1g4UHJEMEd2MmduU2lyd1BReG44M1FYcEgyeHBDOHVJNmNsblFpa0UtMGxOanVFM1B0aEQ5cHFZNkdZblUzQW5Ba0Jpb2NsaDVmR1Bad2FKWEVXUXRiN0ZKYnE2OC1zZXc3Z0o0Szc0U0lkSlNJT043blRZbEI3T21hbVU3SFpxTDMtaEt0T0ZCLXc?oc=5", "source_name": "Market source", "published_at": "2026-07-14T13:55:04+00:00", "published_display": "14 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc. Announces Results from New Healthcare Claims Study of Treatment Patterns of Newly Diagnosed and Established Gad Patients, Including Pharmacotherapy Use, Discontinuation, Switching and Treatment Progression", "summary": "Definium Therapeutics, Inc. announced results from a new healthcare claims study revealing significant unmet needs in Generalized Anxiety Disorder (GAD) treatment. The study, published in CNS Spectrums, highlights frequent discontinuation, switching, and prolonged gaps in care am", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-announces-results-from-new-healthcare-claims-study-of-treatment-patterns-ce7f5edcd08df627", "source_name": "marketscreener.com", "published_at": "2026-07-14T11:40:30", "published_display": "14 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More Than Half of Newly Diagnosed GAD Patients Stopped Therapy", "summary": "A new healthcare claims study published in CNS Spectrums by Definium Therapeutics (DFTX) reveals that 55% of newly diagnosed Generalized Anxiety Disorder (GAD) patients discontinued their initial pharmacotherapy. The study highlights significant unmet needs in GAD treatment, with", "url": "https://www.stocktitan.net/news/DFTX/new-healthcare-claims-study-published-in-cns-spectrums-finds-high-sg82nf1oclaf.html", "source_name": "Stock Titan", "published_at": "2026-07-14T10:40:30", "published_display": "14 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Following Russell Index Removal And The Fair Value Debate", "summary": "Definium Therapeutics (DFTX) is gaining attention after its removal from Russell indexes, with its stock showing significant recent momentum. While one analyst narrative suggests the stock is overvalued at $44.33 with a fair value of $35.23, based on its clinical pipeline and fut", "url": "https://www.sahmcapital.com/news/content/definium-therapeutics-dftx-following-russell-index-removal-and-the-fair-value-debate-2026-07-07", "source_name": "Sahm", "published_at": "2026-07-09T02:40:56", "published_display": "09 Jul 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $60", "summary": "Stifel has reiterated its Buy rating on Definium Therapeutics (DFTX.US) and increased the target price to $60. This continued positive outlook from Stifel suggests confidence in the company's future performance and valuation. The raised target price indicates an expectation of si", "url": "https://www.moomoo.com/news/post/72649606/stifel-maintains-definium-therapeutics-dftxus-with-buy-rating-raises-target", "source_name": "Moomoo", "published_at": "2026-07-09T02:09:01", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Inc (DFTX) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary", "summary": "Definium Therapeutics Inc. presented at the Canaccord Genuity 44th Annual Growth Conference, detailing clinical development for MM120 and MM402. MM120 is advancing to Phase III trials for GAD and MDD, demonstrating durable effects from a single dose, while MM402 is in Phase I for", "url": "https://quartr.com/events/definium-therapeutics-inc-dftx-canaccord-genuity-44th-annual-growth-conference-private-comp_ojsyZ2LG", "source_name": "Quartr", "published_at": "2026-07-09T02:09:01", "published_display": "09 Jul 2026 02:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel raises Definium Therapeutics price target on MDD data", "summary": "Stifel increased its price target for Definium Therapeutics (NASDAQ:DFTX) to $60 from $30, maintaining a Buy rating after strong MDD data for DT120. The firm believes the data significantly de-risks the program and could lead to peak revenues exceeding $4 billion. Definium Therap", "url": "https://www.investing.com/news/analyst-ratings/stifel-raises-definium-therapeutics-price-target-on-mdd-data-93CH-4780314", "source_name": "Investing.com", "published_at": "2026-07-07T22:13:41", "published_display": "07 Jul 2026 22:13", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Announces New Employee Inducement Grants", "summary": "Definium Therapeutics, Inc. announced the issuance of inducement grants to eight new non-executive employees. These grants consist of options to purchase an aggregate of 169,740 common shares, vesting over four years. The grants were approved by the company's Compensation Committ", "url": "https://www.businesswire.com/news/home/20260706280056/en/Definium-Therapeutics-Announces-New-Employee-Inducement-Grants", "source_name": "Business Wire", "published_at": "2026-07-06T20:10:01", "published_display": "06 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Phase 3 DT120 ODT Results in Depression Could Be A Game Changer For Definium Therapeutics (DFTX)", "summary": "Definium Therapeutics announced positive Phase 3 results for its DT120 ODT in major depressive disorder, with the Emerge study meeting its primary and secondary efficacy endpoints. This success strengthens the investment narrative for DFTX, despite previous concerns about funding", "url": "https://www.sahmcapital.com/news/content/positive-phase-3-dt120-odt-results-in-depression-could-be-a-game-changer-for-definium-therapeutics-dftx-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-06T01:13:41", "published_display": "06 Jul 2026 01:13", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Definium Therapeutics, Inc. \u2013 NASDAQ:DFTX", "summary": "This article provides financial data for Definium Therapeutics, Inc. (NASDAQ: DFTX), specifically focusing on its Enterprise Value to EBITDA forward metric. The content highlights the company's financial overview on TradingView, indicating that the market is closed with no trades", "url": "https://www.tradingview.com/symbols/NASDAQ-DFTX/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:42:52", "published_display": "04 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DFTX - Definium Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Definium Therapeutics Inc (DFTX), covering its stock performance, key financial metrics, volatility, and various Greek parameters relevant for options trading. It includes data such as market capitalization, income, sales, EP", "url": "https://finviz.com/stock?t=DFTX&ty=ocv&p=m&ov=chain_strike&s=3", "source_name": "Finviz", "published_at": "2026-07-02T15:39:15", "published_display": "02 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LSD therapy biotech Definium fends off trade-secret lawsuit", "summary": "A federal judge in Delaware dismissed a trade-secret lawsuit against psychedelic therapy developer Definium Therapeutics, filed by clinical-trial provider Signant Health. The judge ruled that Signant's complaint failed to adequately identify protectable trade secrets. Definium, f", "url": "https://www.reuters.com/legal/litigation/lsd-therapy-biotech-definium-fends-off-trade-secret-lawsuit-2026-07-01/", "source_name": "Reuters", "published_at": "2026-07-01T17:09:00", "published_display": "01 Jul 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Completes $805 Million Upsized Public Offering", "summary": "Definium Therapeutics, Inc., formerly Mind Medicine, a late-stage clinical biopharmaceutical company, has successfully completed an upsized $805 million public offering. Hogan Lovells advised Definium Therapeutics on this transaction. Access to the full details of the offering re", "url": "https://globallegalchronicle.com/post-236159/", "source_name": "Global Legal Chronicle", "published_at": "2026-07-01T00:39:56", "published_display": "01 Jul 2026 00:39", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Definium Therapeutics (DFTX)", "summary": "Two healthcare stocks, Crinetics Pharmaceuticals (CRNX) and Definium Therapeutics (DFTX), have received bullish ratings from analysts. Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating for Crinetics Pharmaceuticals with an $83.00 price target, while Paul Matteis a", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DFTX/pressreleases/3047465/analysts-are-bullish-on-top-healthcare-stocks-crinetics-pharmaceuticals-crnx-definium-therapeutics-dftx/", "source_name": "The Globe and Mail", "published_at": "2026-06-30T22:41:00", "published_display": "30 Jun 2026 22:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Definium Therapeutics, Inc. (DFTX) Stock Poised for Further Gains After Positive Emerge Trial Update?", "summary": "Definium Therapeutics, Inc. (NASDAQ:DFTX) recently received a positive update from Robert W. Baird analyst Christopher Chen, who increased the company's price target to $57 from $37, maintaining an Outperform rating following positive Emerge trial results. The biopharmaceutical c", "url": "https://www.insidermonkey.com/blog/is-definium-therapeutics-inc-dftx-stock-poised-for-further-gains-after-positive-emerge-trial-update-1791987/", "source_name": "Insider Monkey", "published_at": "2026-06-30T13:39:56", "published_display": "30 Jun 2026 13:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Canaccord cuts Definium Therapeutics stock price target on share count", "summary": "Canaccord has lowered its price target for Definium Therapeutics (NASDAQ: DFTX) to $58 from $60, while maintaining a Buy rating. This adjustment follows a recent share offering by the company, increasing the share count, but the firm's unadjusted sales projections for its drug ca", "url": "https://www.investing.com/news/analyst-ratings/canaccord-cuts-definium-therapeutics-stock-price-target-on-share-count-93CH-4767600", "source_name": "Investing.com", "published_at": "2026-06-30T11:39:11", "published_display": "30 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000 Value Benchmark", "summary": "Definium Therapeutics, Inc. (NasdaqGS:DFTX) has been removed from the Russell 3000 Value Benchmark. The company, known for developing therapeutics for psychiatric and neurological disorders, is currently trading at $46.55, up 3.56% after hours. Recent news includes its entry into", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-nasdaqgs-dftx-dropped-from-russell-3000-value-benchmark-ce7f5fdeda8cf422", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:55:00", "published_display": "29 Jun 2026 12:55", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Definium Therapeutics, Inc. (NasdaqGS:DFTX) has been removed from the Russell Small Cap Comp Value Benchmark. The company, formerly known as Mind Medicine (MindMed) Inc., is focused on developing therapeutics for psychiatric and neurological disorders, with its lead candidate, DT", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-nasdaqgs-dftx-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8af124", "source_name": "marketscreener.com", "published_at": "2026-06-29T10:10:20", "published_display": "29 Jun 2026 10:10", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc.(NasdaqGS:DFTX) dropped from Russell 3000E Growth Benchmark", "summary": "Definium Therapeutics, Inc. (NasdaqGS:DFTX) has been removed from the Russell 3000E Growth Benchmark. Despite this change, the company continues to advance its pipeline of therapeutics for psychiatric and neurological disorders, including DT120 ODT, which has received FDA Breakth", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-nasdaqgs-dftx-dropped-from-russell-3000e-growth-benchmark-ce7f5fdedf89f625", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:41:42", "published_display": "29 Jun 2026 08:41", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics, Inc.(NasdaqGS: DFTX) dropped from Russell Microcap Index", "summary": "Definium Therapeutics, Inc. (NasdaqGS: DFTX) has been removed from the Russell Microcap Index. The company is focused on developing therapeutics for psychiatric and neurological disorders, with a lead candidate, DT120 ODT, targeting generalized anxiety disorder (GAD) and major de", "url": "https://www.marketscreener.com/news/definium-therapeutics-inc-nasdaqgs-dftx-dropped-from-russell-microcap-index-ce7f5fdeda80ff21", "source_name": "marketscreener.com", "published_at": "2026-06-29T05:41:42", "published_display": "29 Jun 2026 05:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Definium Therapeutics, Inc. \u2013 NASDAQ:DFTX", "summary": "This article displays a financial metric, the \"Price to sales forward,\" for Definium Therapeutics, Inc. (NASDAQ: DFTX). It presents this data within the TradingView platform's market analysis section, indicating that it is a snapshot of financial performance for the company. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-DFTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T03:39:40", "published_display": "28 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Definium Therapeutics, Inc. \u2013 NASDAQ:DFTX", "summary": "This article provides financial information for Definium Therapeutics, Inc. (NASDAQ: DFTX), specifically focusing on its forward price-to-earnings ratio. It is presented in a data-centric format from TradingView, indicating market status, and links to various financial data sourc", "url": "https://www.tradingview.com/symbols/NASDAQ-DFTX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:11:05", "published_display": "27 Jun 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Definium Therapeutics, Inc. \u2013 HAM:MMQ0", "summary": "This article provides the \"Price to book forward\" for Definium Therapeutics, Inc. (HAM:MMQ0), a pharmaceutical company listed on the Hamburg Stock Exchange. The current market status is closed with no trades. The information is presented within the TradingView platform, which off", "url": "https://www.tradingview.com/symbols/HAM-MMQ0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T16:11:05", "published_display": "27 Jun 2026 16:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings ratio of Definium Therapeutics, Inc. \u2013 HAM:MMQ0", "summary": "The article focuses on the price-to-earnings ratio of Definium Therapeutics, Inc. (HAM:MMQ0), a company listed on the Hamburg Stock Exchange. It provides financial overview, but no actual ratio is displayed, indicating that the market is closed with no trades.", "url": "https://www.tradingview.com/symbols/HAM-MMQ0/financials-statistics-and-ratios/price-earnings/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:13", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Definium Therapeutics, Inc. Stocks", "summary": "This article lists various Exchange Traded Funds (ETFs) that hold stocks of Definium Therapeutics, Inc. It provides a detailed table with each ETF's market value, weight of Definium stock, issuer, management style, focus, expense ratio, assets under management (AUM), current pric", "url": "https://www.tradingview.com/symbols/HAM-MMQ0/etfs/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:13", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium (DFTX) CEO sells 29,208 shares to cover RSU tax obligations", "summary": "Definium Therapeutics, Inc. CEO Robert Barrow sold 29,208 common shares at $45.03 each on June 25, 2026. This transaction was conducted to satisfy withholding tax obligations related to vested restricted stock units under a pre-arranged Rule 10b5-1 sell-to-cover plan. Following t", "url": "https://www.stocktitan.net/sec-filings/DFTX/form-4-definium-therapeutics-inc-insider-trading-activity-f11cef1c86bf.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:40:13", "published_display": "26 Jun 2026 20:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Definium Therapeutics, Inc. Insider Trading Activity", "summary": "Definium Therapeutics CFO Brandi Roberts disposed of 3,013 common shares at $45.03 each on June 25, 2026. This transaction was a \"sell-to-cover\" event to satisfy tax obligations from vested restricted stock units, executed under a pre-arranged Rule 10b5-1 trading plan. Following ", "url": "https://www.stocktitan.net/sec-filings/DFTX/form-4-definium-therapeutics-inc-insider-trading-activity-ada560f26a68.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:30:37", "published_display": "26 Jun 2026 20:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Lands Phase 3 Win And Raises $700 Million For DT120", "summary": "Definium Therapeutics (NasdaqGS:DFTX) announced positive topline Phase 3 results for DT120, its major depressive disorder treatment, and simultaneously completed a US$700 million equity offering. This funding is intended to support the regulatory and commercialization efforts for", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dftx/definium-therapeutics/news/definium-therapeutics-dftx-lands-phase-3-win-and-raises-700", "source_name": "Simply Wall Street", "published_at": "2026-06-26T13:40:26", "published_display": "26 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium closes $805M upsized stock offering | DFTX Stock News", "summary": "Definium Therapeutics, Inc. announced the closing of its upsized underwritten public offering, raising $805 million. The offering included the full exercise of the underwriters\u2019 option to purchase additional shares, with all 23,676,471 common shares sold at $34.00 each. Definium ", "url": "https://www.stocktitan.net/news/DFTX/definium-therapeutics-inc-announces-closing-of-805-million-upsized-umbrglb2boxi.html", "source_name": "Stock Titan", "published_at": "2026-06-26T09:41:42", "published_display": "26 Jun 2026 09:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics Closes Public Offering of Common Shares", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/definium-therapeutics-closes-public-offering-210201361.html", "source_name": "MT Newswires", "published_at": "2026-06-25T21:02:01+00:00", "published_display": "25 Jun 2026 21:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Definium Therapeutics (DFTX) Is Up 49.8% After DT120 Phase 3 Win And $700 Million Raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPcFRqUTZRRlBUaktHX2E3U096V25PWWJRUzh3YXJ1X0ZUVHNUNk9xendjY25CWVV5TXJ5N09jVmF1TV9EcUNhVUxHSUdHbmtkeWxCM1B2czdfbzBNVEw0bTRFQ2dYOTVaNnp2TlpLQWE1TFRwOGFCVzJUZkJ6RzdaTTBMb2ZFZjg3U1A4VnNwUHFIM1Nyb1lmaFZB?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPV0xlbTIxelBIUV9wWm9PYzUxZ3IxOTQwaFJQTDQwQWZYVVd6ODZhRnhmM2dEWDV1RzdTTkwxOUxvZWQ0TWhEbzYxWXBRRmY0ZHdKQkFSajExcFY4WldOWE9kd254amhwZUszdk5xR3RwNDM3aFZua3ZaWGtya3pnSHJLUFUyc3NvQjlZZXl3ODNBRy1Sb1BfVmRhVlo5U2pjYnB2Zy00VlU1aGhRRUlVUFRXLVdaNVZqcUc1eUQtUzR2WTQ?oc=5", "source_name": "TradingView", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Posts Phase 3 Win And Plans Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPZVJTX1JXeHYyb0FHZFJPdjRIVnJ2d0djdHVXOU5KZm1hc2lrRnl5aU5RUXVCLUpqZU05NzJnV2RnMnlCdU8yNjFIQWhReW5JUl9sUEZVeHFmN3h5allyMXNrbEFhaXNGNXJ5MzI0SWFhVU5DR3FXaHpaMm44SF9hTHlvbzh6U1Q5cnI4aS1CbE9qY3ByZHBacS0wVkJaei1B?oc=5", "source_name": "Market source", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics seeks $500M in a public share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNVEdZSVJYUlNEUk80alhqTVFlbXgzdEs5YVY4QWQ5c2xJWUR0SkIzUDJmYWxlNVhhZjRJTmhLbTBrNHZFTWZyRlVITzlsR1JWazBtVU5ZdTItNkdJRFJaamtyQ2NRdWJwUlZFQnJMOHdsWW5mZFZqdnpLZXR0RXdLR3FQeWVsQ015Q0FkRmNmMGoycUtYT3hFVW15LVdlTVVFWWk3UGpIWnk2Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T20:03:47+00:00", "published_display": "22 Jun 2026 20:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink raises Definium Therapeutics stock price target on MDD data", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPZWJhNkVTV2U0TWVaX2RQNUhFS3J4eTBlRkk0MTZQN0hPMEk1bG1DQnlqZ0c2Q3BWVGR5OU5ZVWVhSEIwYTVocW05UldlQVdqaHFSZldQZ2lEQ29GVVY2aWdRb21OakwxNkd0OW9rSjJkU0ZfbEdtb1hyOHY3YWFqMnhYYXpJWDBTYkpUU3RFQTlRZDZvV05BOWVEdjZyWlJlQjZSTldULUVkNzdZajNtOWoxQ0MtWkhXZTk0bHQ4blRDQ2NfWkE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) reports positive Phase 3 Emerge results for DT120 ODT in major depressive disorder", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOWFVtRlB4c19jUVNUaHJaR21QUlVzT2FNaXNXbVk0UlZsRUcwaGh3YWphRVdFTUVCSENnVW54VGFxZlFrNjRyNk13QWw3RHZEMzRmSHNvODlRVTVvdFItcmpEZ0NsdXVqeEtCczFSc1l6MUZNMTNWNnR3bG5NSzRROHpmN1BiQXBOSldKb3BQU1p5Ui1HbURDbmdQYXo5Vzd4VlJoWmtZajlrSXN1ZjQ5ZjNFWXI?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) CEO receives 375,000 performance share units", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPTkotMmxQME14dktRYmtXOUpvZ2JyeU83WjEyVmFEbXI1OEZsR05tc1kyYUpBTDdmdlIzVlI5Nl90WGxiUzVSWDdfWTFZU1lKak4xMWdSOHBGUmJjdFpMMzRwVjFRMzRyZjA0QzJwOFpidWc4cGI3MHItdUdCRXc5cFhUb1VOZDlQdWwzQUhHS1JqTVpYM0lMWmk4blQ1bUdoZjgxcTFjVU03elc1aDB3ejNCX2ZJZHFjbFI0?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Hits New High on Impressive Drug Candidate Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOcEdETjlPUTZ5N0swLUVza1RrZDNkZEQ1WFN3TjE5eGhvdkc5UFE0Tk1VTDl3a1dfOFA5QVdiMWZ4dkRGUzFnT25qWWtXZHRKWUJXeVhwbWw1M0ZQbGZ2YjcyYmlwc1NNcjUzTUpqaFVDd1RhN2dmaUYyeXA5UnhZZEpyUV9kX2V3aUZPdDBkS2lETnIxRGkwSnAzTVFJdw?oc=5", "source_name": "Market source", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium sets webcast on Phase 3 depression study results for June 22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxQX3doMktpbktIaUxiVm1helUxUXdHbUQwTFZTOFpkUkpUYWVyV3RYNlJDWDFoeThCUXVqbklBanEtTVZyTWFrYjMweHhDT0wtaDN3QmJBZnJZNkJUVXJVNUdJNG9INjB6VkpkbHlCOVFCTnhEZFRwWnFHdUxvZWNpdjdaQy1wZ2wyQ2k2N1pxOUFjQjhZUDlXQ0dEeGFTckp2UEljejdyRG5NcFZNQzFSRGtlUVMxdTAtUlFscHhoNHE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) awards RSUs and stock options to director Krebs", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPb0piR1hoMW11akRuVWxLT2xvZGZCMVYwbEY0Mm1IcWlPeW1PN042SXQ3UEpWSG9LYktyZkxJbnp5MjFFWWdsRzFIV202SDcwVUpnb2h0ZTh1UUxBYk8xMmtQYjU4cXRuV2dld0tycDB2UXMyRWhLbzNfZ1NzWHY4c2RoOEowcnFXaXdkalhZRk5ack5sSVJwSmJUMmtnenFBSjN2MnlSSGMtcVI5OWFodVUtWE51c1RJbWdr?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) director receives RSU and stock option grants", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUk9Ma1lIWjQzWXYtTGF4SlBaU1dhYUl0bWsyTGgtRGdCQ1FUOV9PcUVIT0hzZjR0M284UTV1WFRNMFZYeU5tbWJRNkdhQVBPcXYwRVJMdHBjank3WHpIN0xVUUZLRDlfcVh6VXdSb2l5T01VR2R3NEpwNDRrbmpWd2JtcE9uUVBaTTBlWmJZOWM2X0NoR19FY3dQNHRZSk9sMkItLVNJVXZmMVlNV0VkUy1NVmFUYnhLbEhF?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Definium Therapeutics (DFTX) Valuation As Shares Show Strong Recent Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNS0dKMzh1YnM4dUpEeFN1WGs0Z0xVbDEzRDh2aXJJbnIzaHlSTDJuS0FSQUlxM1Fub2lhRzg5QVlCX0lTXzU1clNRU1FvSmtVUDRINklXMjljamZSQkNJVDZrRGI1SVFmcXV5ZTV3TFVERVNkak0yZlpNci1qWWVCUWpHZUs0VGVJQUxNeUp5TkFBTXEwT2ROSHlsZmJXZnJFRTlkajRaUS0wTVprX3Nn?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Begins Phase 3 Study for Major Depr", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPTzBrVG9reTlCaE51UE1KbjlNOGxkLWxtX01MYXVfSlJ2WHlvX05rVVR5MUdxckZVSHFRX2tGWEdhclgtc0FfeDRObGdpNnBIMXE0aExQSF9VdkhMNlZOYmg5ZHVzZkF5WTBjMXhjd09LRmxnM1E0RW5TenV1clJ3WnpjSk1WMnpsR3Rocnl4bkZzYlY0T0d0d0RMSEpxS3l4N0xMeTNCMjlzQWlCV0pDU2RhV3JiNTVISTAzTFZfcWhrOFZQLWVF?oc=5", "source_name": "GuruFocus", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPcEhCcHZzeVY4bjNmYWkxTmhtanhPUFhEa0VoVGRFbnZTaU4zVWhIdkdRTF84QVU0TXM4T291cld6cF9uZzhQaE0xNWdGa3YxSksyMk82V0tFWnVLR05TMTUxXzRTVjdHLWRuejYyRHFSTGNxQkw1SVJjZHcwWHpRd0dwMXIyTGJ5aWMtVkowUW1LUExwQjUxRXZoV2pRZi1WNENFejNfVVJOTEllSUFB?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Definium\u2019s Q1 2026 EPS miss overshadows strategic advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQNGtjYXJFZ3VQaklnZ2J1NzR0MU56UlRPczJJMXJBLU9QSHF1OXFyWEtiMnJrYi1tNUhVQ05DOFA0d2VMR0szUTV1SUJOZnFnS1hqNWZxWnplX1Rnb0plUklwS1MzbF9kYW44ZnVjTXBWaXRaWXROWmcxdHJ6VEVNc3BfVjNERzV0VktIOW9CUmpwVnNteUYzYnQtNXFCaUVWcmRJeDlBMzFvWHBoTFloZkttck1QbVlHYmhTblh3SThwcTF1aUpiYTM4ZEhORkYxSEdtbw?oc=5", "source_name": "Investing.com", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics stock hits 52-week high at 25.63 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQZDJqNlgxbVRDci12TWYwQVVsTm9EVUZ4Q2VmbG9QTjFraWNBUlIwTDdCWW4wMFFCak9EdWt1ODhDbElPRjJVX25ZOVBoNDRwSDFUS1dMNWRJSTNPWTNaT1RWS3puUjN1Qkl3SGtoX3h0M0ZhYVVONlF6cFhWdlJySHlpVWY1UDBhYXI3SU5qaVk5bG9CaGk4TFJOX1N3cmw4N1J5dlhEZkRVNkZkSnk3NE9obw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Definium Therapeutics stock hits 52-week high at 21.99 USD", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOT0FRa3VNRnMyRnNlZDFMcFhWT3lFTDBTMUs1SGRYMENoREdUcGs3bUJpT2ZNb2FqU1FjeHF3U2xSdURvVDdmRUZvSVVURXh3MkEweUdqZ29yZEk3YzAyRmo2d0VtVmhJWGVwVXE2dmJVeUdUSXFLTXg4Rk5pbC04ZTFCWmVZc19vQ2RtaWhnc1BWYnF4MTJjV2ZpUWxjQzBHTVJHaDZBcTJtUUJoQm9sd283RQ?oc=5", "source_name": "Investing.com", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 108, "total_relevant": 62, "sentiment_summary": {"positive": 22, "negative": 8, "neutral": 32, "score": 56, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 20.15, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.9, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 22, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 44.29, "latest_week": "2026-07-17", "one_week_move": -5.9, "four_week_move": 80.9, "twelve_week_move": 97.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.851034, "market_dynamics_buy_signal": false, "relative_strength": 130.046593, "fair_value_gap": 338.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.3701, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.9% over one week, +80.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 10}, {"label": "TradingView", "count": 7}, {"label": "Investing.com", "count": 6}, {"label": "marketscreener.com", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Sahm", "count": 2}, {"label": "Morningstar", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 8}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-5.9% over one week, +80.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology"}], "updated_at": "2026-07-18T10:25:24.184139+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}